Title |
Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC)
|
---|---|
Published in |
BMC Neurology, July 2016
|
DOI | 10.1186/s12883-016-0623-2 |
Pubmed ID | |
Authors |
Robert Zivadinov, Diane L. Cookfair, Lauren Krupp, Aaron E. Miller, Neil Lava, Patricia K. Coyle, Andrew D. Goodman, Burk Jubelt, Michael Lenihan, Joseph Herbert, Malcolm Gottesman, David H. Snyder, Brian R. Apatoff, Barbara E. Teter, Allan B. Perel, Frederick Munschauer, Bianca Weinstock-Guttman |
Abstract |
This retrospective analysis explored prognostic factors associated with a benign multiple sclerosis (BMS) disease course at baseline and over the 4-year follow-up. Patients from the centralized New York State Multiple Sclerosis Consortium registry were classified as having BMS according to 3 different criteria centered on disease duration and disability. Additional analyses explored prognostic factors associated with BMS using the most conservative disability criteria (Expanded Disability Status Scale ≤2 and disease duration ≥10 years). Among 6258 patients who fulfilled eligibility criteria, 19.8 % to 33.3 % were characterized as having BMS, at baseline depending on classification criteria used. Positive prognostic factors for BMS at baseline included female sex (p < 0.0001) and younger age at onset (p < 0.0001); negative prognostic factors included progressive-onset type of MS and African-American race. Of the 1237 BMS patients (per most conservative criteria), 742 were followed for a median of 4 years to explore effect of disease-modifying treatment (DMT) on benign status. DMT (p = 0.009) and longer disease duration (p = 0.007) were the only significant positive predictors of maintaining BMS at follow-up. The protective effect was stronger for patients taking DMT at both enrollment and follow-up (OR = 0.71; p = 0.006). There is a need for development of more reliable prognostic indicators of BMS. Use of DMT was significantly associated with maintaining a benign disease state. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 29% |
United Kingdom | 1 | 14% |
France | 1 | 14% |
Qatar | 1 | 14% |
Unknown | 2 | 29% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 71% |
Practitioners (doctors, other healthcare professionals) | 2 | 29% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 2% |
Unknown | 45 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 7 | 15% |
Researcher | 6 | 13% |
Student > Master | 5 | 11% |
Student > Bachelor | 4 | 9% |
Student > Ph. D. Student | 3 | 7% |
Other | 8 | 17% |
Unknown | 13 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 39% |
Neuroscience | 4 | 9% |
Nursing and Health Professions | 3 | 7% |
Biochemistry, Genetics and Molecular Biology | 1 | 2% |
Immunology and Microbiology | 1 | 2% |
Other | 5 | 11% |
Unknown | 14 | 30% |